Greg Mullen, PhD
Chief Operating Officer
Greg Mullen has held executive roles in the healthcare sector for the last ten years as Head of Research & Development at Oxford Immunotec, Chief Scientific Officer at Mediso and Chief Executive Officer at Theragnostics. Previously, he was a leading researcher at the US National Institutes of Health and King’s College London, UK. He has over 100 peer reviewed publications, focusing on translational medicine in immunology, oncology and radiopharmaceutical development. Greg has extensive clinical, product and business development experience, and in 2022, this culminated in the USFDA approval of the radiopharmaceutical diagnostic NEPHROSCANTM, and in 2023 in the merger of Theragnostics with Ariceum.
Greg has a PhD in chemistry from the University of Kent, UK. He was a research fellow in chemistry at the University of Oxford, UK, and an immunology research fellow at NIH, US.